Education
About Us
Working with TipRanks
Follow Us
Metavia Inc. (MTVA)
:MTVA
MTVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $5.71
Previous CloseN/A
Volume36.62K
Average Volume (3M)24.48K
Market Cap
$12.58M
Enterprise Value$10.86M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)100.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 27, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.77
Shares Outstanding8,616,010
10 Day Avg. Volume24,899
30 Day Avg. Volume24,477
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside653.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
MetaVia News
PremiumCompany Announcements
MetaVia Advances Therapeutics with Promising Trial Updates
PremiumCompany Announcements
MetaVia Reports Positive Phase 2a Clinical Trial Results---
Bulls Say, Bears Say
Bulls Say
Product ComparisonDA-1726 was also comparable or superior to survodutide with greater weight reductions than survodutide and comparable food consumption.
Product PerformanceDA-1726 showed comparable weight loss, but also showed improvements in key metabolic measures including glucose, triglycerides, and cholesterol.
Bears Say
Market ReactionShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space.
---
Ownership Overview
64.23% Insiders
1.10% Mutual Funds
8.46% Other Institutional Investors
25.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MTVA FAQ
What was Metavia Inc.’s price range in the past 12 months?
Metavia Inc. lowest stock price was $1.29 and its highest was $5.71 in the past 12 months.
What is Metavia Inc.’s market cap?
Metavia Inc.’s market cap is $12.58M.
When is Metavia Inc.’s upcoming earnings report date?
Metavia Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 21 days.
How were Metavia Inc.’s earnings last quarter?
Metavia Inc. released its earnings results on Nov 07, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.73 by $0.18.
Is Metavia Inc. overvalued?
According to Wall Street analysts Metavia Inc.’s price is currently Undervalued.
Does Metavia Inc. pay dividends?
Metavia Inc. does not currently pay dividends.
What is Metavia Inc.’s EPS estimate?
Metavia Inc.’s EPS estimate is -0.68.
How many shares outstanding does Metavia Inc. have?
Metavia Inc. has 8,616,010 shares outstanding.
What happened to Metavia Inc.’s price movement after its last earnings report?
Metavia Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.73. Following the earnings report the stock price went down -2.19%.
Which hedge fund is a major shareholder of Metavia Inc.?
Currently, no hedge funds are holding shares in MTVA
---
Company Description
Metavia Inc.
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
---
MTVA Stock 12 Month Forecast
Average Price Target
$11.00
▲(653.42% Upside)
Technical Analysis
Best Analysts Covering MTVA
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-50.64%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.64% per trade.
---